Clinical trial NCT00307827: Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis (IVSR-UC)
Official title: A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects With Intravenous Steroid-refractory Ulcerative Colitis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Ulcerative Colitis
Keywords: Steroid-Refractory
IVSR-UC
Ulcerative Colitis
Lead sponsor: Abbott
Sponsor class: INDUSTRY
First posted: 2006-03-28
Enrollment: 38
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the efficacy, immunogenicity, and safety of various doses of visilizumab in subjects with intravenous steroid-refractory ulcerative colitis (IVSR-UC) and to evaluate optimal dosing.

Detailed description: PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.

Eligibility criteria: Inclusion Criteria

Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:

* Males and females, 18 years of age or older.
* Diagnosis of ulcerative colitis (UC), as verified by endoscopy performed within 60 months prior to consent.
* Severe active disease, as defined by modified Truelove Witts severity index (MTWSI) \>= 11 at consent, with a confirmatory MTWSI \>= 10 on or after the fifth consecutive day of intravenous (IV) steroids and within 1 day prior to randomization.
* Mayo score \>= 10 and Mayo mucosal subscore \>= 2 after a minimum of 3 consecutive days (ie, on or after the fourth consecutive day) of IV steroids.
* Adequate contraception from the day of consent through 3 months after the last dose of study drug.
* Negative serum pregnancy test at screening.
* Negative Clostridium difficile test within 10 days prior to randomization.
* Signed and dated informed consent and Health Insurance Portability and Accountability Act (HIPAA) if applicable.

Exclusion Criteria

Subjects will be ineligible for this study if they meet any one of the following criteria:

* UC requiring immediate intervention.
* History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis
* Presence of ileostomy.
* White blood cell count less than 2.5 x 10\^3/mcL; platelet count less than 150 x 10\^3/mcL; or hemoglobin level less than 8 g/dL.
* Active medically significant infections, particularly those of viral etiology, eg, known cytomegalovirus (CMV) colitis. This includes any incidence of medically significant opportunistic infections within the past 12 months.
* Live vaccination within 6 weeks prior to randomization.
* Significant organ dysfunction, including cardiac, renal, liver, central nervous system (CNS), pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality.
* History or treatment of lymphoproliferative disorder (LPD) or malignancy within the past 5 years (excluding nonmelanoma skin cancer or carcinoma in situ of the cervix).
* Seropositivity for infection with human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV).
* Pregnancy or nursing.
* Treatment with a first dose of infliximab or another anti-TNF-a drug within 4 weeks of randomization, or treatment with a subsequent dose of an anti-TNF-a drug within 2 weeks of randomization.
* Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to randomization.
* Treatment with any other investigational drugs or therapies within 60 days prior to randomization, except those mentioned in the two exclusion criteria above.
* Unwilling or unable to discontinue all UC drugs, except glucocorticoids and oral 5-ASA, immediately prior to randomization.
* Nontherapeutic levels of chronic antiseizure medications in subjects with a prior history of seizures.
* Any condition that, in the investigator's opinion, makes the subject unsuitable for study participation.

Primary outcomes:
measure: Proportion of subjects in each of the three visilizumab dose groups who respond to treatment in the dose-exploration portion of this study (Stage 1).
timeFrame: Day 45
Secondary outcomes:
measure: Comparison of subjects in the three visilizumab dose groups
timeFrame: During the course of the study
Other outcomes:
Locations:
city: Savannah
country: United States
facility: Site Reference ID/Investigator# 71894
state: Georgia
city: Worcester
country: United States
facility: Site Reference ID/Investigator# 71897
state: Massachusetts
city: Manhasset
country: United States
facility: Site Reference ID/Investigator# 71913
state: New York
city: Chapel Hill
country: United States
facility: Site Reference ID/Investigator# 71895
state: North Carolina
city: Cleveland
country: United States
facility: Site Reference ID/Investigator# 71896
state: Ohio
city: Hamilton
country: Canada
facility: Site Reference ID/Investigator# 71875
city: Winnipeg
country: Canada
facility: Site Reference ID/Investigator# 71873
city: Osijek
country: Croatia
facility: Site Reference ID/Investigator# 72338
city: Zagreb
country: Croatia
facility: Site Reference ID/Investigator# 72334
city: Bologna
country: Italy
facility: Site Reference ID/Investigator# 72345
city: Moscow
country: Russian Federation
facility: Site Reference ID/Investigator# 72314
city: Nizhny-Novgorod
country: Russian Federation
facility: Site Reference ID/Investigator# 71953
city: St. Petersburg
country: Russian Federation
facility: Site Reference ID/Investigator# 72315
city: St. Petersburg
country: Russian Federation
facility: Site Reference ID/Investigator# 72342
city: Badalona - Barcelona
country: Spain
facility: Site Reference ID/Investigator# 72368
city: Majadahonda (Madrid)
country: Spain
facility: Site Reference ID/Investigator# 72366
Study officials:
affiliation: Abbott
name: Mihail Obrocea, MD
role: STUDY_DIRECTOR
References: